Ten months af­ter dev­as­tat­ing fail­ure, Roche says it sees path for­ward for Hunt­ing­ton’s drug

If you had to pick 2021’s biggest drug de­vel­op­ment dis­ap­point­ment, it’d be hard to over­look the Roche-Io­n­is Hunt­ing­ton’s dis­ease tri­al.

The Phase III study rep­re­sent­ed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER